A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday. Specifically, these exchange-traded funds bought roughly $4.6 million worth of CRISPR Therapeutics AG (NASDAQ: CRSP), as the prices of these funds were down about 1% on Wednesday. Note that their performance is fairly negative in the past year.
[in-text-ad]
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 14,400 shares of CRISPR, and ARK Innovation ETF (NYSEARCA: ARKK) scooped up 45,500 shares. At Wednesday’s closing price, this would have valued the sales at roughly $4.6 million altogether. Even though this is a small fraction of their total holdings, every little bit counts. The innovation ETF is down about 24% and the other is down closer to 36% in the past year.
Check out all the ARK Invest trades for Wednesday as well:
| Fund | Direction | Ticker | Name | Shares |
|---|---|---|---|---|
| ARKF | Buy | TDOC | TELADOC HEALTH | 10,000 |
| ARKG | Buy | TDOC | TELADOC HEALTH | 22,500 |
| ARKG | Buy | SGFY | SIGNIFY HEALTH | 105,770 |
| ARKG | Buy | PSNL | PERSONALIS | 33,753 |
| ARKG | Buy | MASS | 908 DEVICES | 56,909 |
| ARKG | Buy | CRSP | CRISPR THERAPEUTICS | 14,400 |
| ARKG | Buy | BLI | BERKELEY LIGHTS | 50,528 |
| ARKG | Buy | BEAM | BEAM THERAPEUTICS | 5,855 |
| ARKG | Sell | TXG | 10X GENOMICS | 33,989 |
| ARKG | Sell | VRTX | VERTEX PHARMACEUTICALS | 24,007 |
| ARKK | Buy | VCYT | VERACYTE | 38,715 |
| ARKK | Buy | TWOU | 2U | 107,448 |
| ARKK | Buy | TDOC | TELADOC HEALTH | 97,300 |
| ARKK | Buy | SSYS | STRATASYS | 249,771 |
| ARKK | Buy | NVTA | INVITAE | 51,355 |
| ARKK | Buy | CRSP | CRISPR THERAPEUTICS | 45,500 |
| ARKK | Sell | TSLA | TESLA | 22,816 |
| ARKQ | Buy | XPEV | XPENG | 43,100 |
| ARKQ | Buy | PATH | UIPATH | 31,830 |
| ARKQ | Buy | MTLS | MATERIALISE | 20,338 |
| ARKQ | Sell | TSLA | TESLA | 5,069 |
| ARKW | Buy | TDOC | TELADOC HEALTH | 17,000 |
| ARKX | Buy | BLDE | BLADE AIR MOBILITY | 28,372 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of a673b.bigscoots-temp.com.
“The Next NVIDIA” Could Change Your Life
If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
Click here to download your FREE copy.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
